Na faasilasila e Aspen Neuroscience, Inc. o le masina nei o le a faʻalauiloaina ai le suʻesuʻega muamua o le suʻesuʻega o tagata maʻi, o loʻo galulue faʻatasi ma le tele o nofoaga suʻesuʻe ile US.

O le su'esu'ega a le kamupani o le Trial-Ready Cohort Study ose la'asaga muamua lea i le fa'auluina o se Talosaga Investigational New Drug (IND) ma le US Food & Drug Administration mo le ANPD001, o lona sui muamua o le atina'eina o togafitiga mo togafitiga o le ma'i idiopathic Parkinson (PD). Ole Su'esu'ega Fa'ata'ita'i-Sauni ole a tu'uina atu fa'amatalaga ile su'esu'eina ole su'esu'ega fa'apitoa ole gasegase mo le Fuafuaga 1/2A fa'ata'ita'iga muamua a le kamupani ile ANPD001. O le a faʻasalalau e le kamupani le tele o nofoaga suʻesuʻe a Amerika i le tautotogo atoa.

"O se taimi iloga lenei mo gasegase ma mo le Aspen Neuroscience team, a o matou tatalaina la matou suʻesuʻega muamua suʻesuʻega e faʻavave ai la matou suʻesuʻega i le iPSC e maua mai ai togafitiga faʻafomaʻi mo le maʻi o Parkinson," o le tala lea a Damien McDevitt, Ph.D., peresitene ma le pule sili. ofisa fa'atonu. “Matou te fiafia ma matua fa'amaulalo e amata le isi la'asaga i le masina o le Fa'aaliga o Parkinson. Ose la'asaga taua lea mo le fa'alapotopotoga o gasegase, mo tausi soifua maloloina ma le neuroscience field.

O le PD o le faʻamaʻi lona lua sili ona taatele o le neurodegenerative, e aʻafia ai le tusa ma le tasi miliona Amerika ma sili atu i le sefulu miliona tagata i le lalolagi atoa. E oʻo lava i le tulaga o loʻo i ai nei o le tausiga o togafitiga, e mafai e tagata gasegase ona atiaʻe faʻalavelave faʻalavelave faʻalavelave ona o le leiloa o le dopamine neurons i le faiʻai; e tusa ma le 50% e leiloa a'o le'i maua le su'esu'ega.

Aspen Neuroscience o le kamupani taʻutaʻua o loʻo atiaʻe se sui faʻapitoa faʻapitoa e mafai ona faʻaumatia ai le manaʻoga mo togafitiga immunosuppressive. O le auala e fa'aogaina ai le iPSCs e maua mai i le pa'u o le tagata ma'i e maua ai le sui o le dopamine neurons mo le toe fa'afo'iina i totonu o le ma'i lava e tasi. Fausia mai se biopsy paʻu faigofie, o le a suʻesuʻeina sela o maʻi taʻitasi mo le faʻaogaina lelei e faʻaaoga ai meafaigaluega genomics faʻavae AI, aʻo leʻi faʻapipiʻiina mo le faʻaogaina o falemaʻi.

OA MEA E AVEA MAI LENEI TUSI:

“This is an historic moment for patients and for the Aspen Neuroscience team, as we open our first screening study to expedite our investigation of iPSC-derived cell replacement therapies for Parkinson’s disease,”.
announced that this month it will launch the first patient screening study of its kind, working with multiple clinical screening sites in the U.
This is a significant step forward for the patient community, for health care providers and the neuroscience field.